Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.01 USD | -0.69% | -0.50% | -19.53% |
May. 07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
May. 02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.53% | 81.63B | |
+33.77% | 700B | |
-4.94% | 358B | |
+18.87% | 330B | |
+3.48% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+5.65% | 161B | |
-1.86% | 157B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Transcript : Gilead Sciences, Inc., Q2 2023 Earnings Call, Aug 03, 2023